PMC:7461420 / 28781-28962 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T144","span":{"begin":14,"end":18},"obj":"Body_part"},{"id":"T145","span":{"begin":92,"end":97},"obj":"Body_part"},{"id":"T146","span":{"begin":107,"end":115},"obj":"Body_part"},{"id":"T147","span":{"begin":117,"end":126},"obj":"Body_part"}],"attributes":[{"id":"A144","pred":"fma_id","subj":"T144","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A145","pred":"fma_id","subj":"T145","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A146","pred":"fma_id","subj":"T146","obj":"http://purl.org/sig/ont/fma/fma62262"},{"id":"A147","pred":"fma_id","subj":"T147","obj":"http://purl.org/sig/ont/fma/fma67180"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T18","span":{"begin":14,"end":18},"obj":"Body_part"}],"attributes":[{"id":"A18","pred":"uberon_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T165","span":{"begin":14,"end":27},"obj":"Disease"}],"attributes":[{"id":"A165","pred":"mondo_id","subj":"T165","obj":"http://purl.obolibrary.org/obo/MONDO_0005275"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T317","span":{"begin":14,"end":18},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T318","span":{"begin":14,"end":18},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T319","span":{"begin":92,"end":97},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T256","span":{"begin":61,"end":71},"obj":"Chemical"}],"attributes":[{"id":"A256","pred":"chebi_id","subj":"T256","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T13","span":{"begin":14,"end":27},"obj":"Phenotype"}],"attributes":[{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0002088"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-PubTator","denotations":[{"id":"917","span":{"begin":14,"end":27},"obj":"Disease"},{"id":"919","span":{"begin":72,"end":76},"obj":"Species"}],"attributes":[{"id":"A917","pred":"tao:has_database_id","subj":"917","obj":"MESH:D008171"},{"id":"A919","pred":"tao:has_database_id","subj":"919","obj":"Tax:11118"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}

{"project":"LitCovid-sentences","denotations":[{"id":"T270","span":{"begin":29,"end":31},"obj":"Sentence"},{"id":"T271","span":{"begin":33,"end":71},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" approach for lung diseases. 97\n\n2.3 Proteolytic processing inhibitors\nCoVs enter the host cells via both clathrin (endosomal) and nonclathrin pathways (nonendosomal); however, bot"}